Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysis.
Antonios ValachisEleftherios P MamounasElizabeth A MittendorfNaoki HayashiMakoto IshitobiClara NatoliFlorian FitzalIsabel T RubioDaniel G TiezziHee-Chul ShinStewart J AndersonKelly K HuntNaoko MatsudaShozo OhsumiAthina TotomiCecilia NilssonPublished in: Cancer (2018)
BCT after NCT appears to be an oncologically safe procedure for a large percentage of patients with breast cancer. Two easy-to-use clinical scores were developed that can help clinicians to identify patients at higher risk of LR and LRR after NCT and BCT and individualize the postoperative treatment plan and follow-up. Cancer 2018;124:2923-30. © 2018 American Cancer Society.
Keyphrases
- neoadjuvant chemotherapy
- papillary thyroid
- systematic review
- locally advanced
- lymph node
- squamous cell
- sentinel lymph node
- patients undergoing
- palliative care
- minimally invasive
- case report
- lymph node metastasis
- radiation therapy
- randomized controlled trial
- meta analyses
- rectal cancer
- mesenchymal stem cells
- newly diagnosed
- smoking cessation